信必可都保和舒利迭治疗支气管哮喘的疗效对比  

The effect comparison of Symbicort Turbuhaler and Seretide in the treatment of patients with bronchial asthma

作　　者：罗虹[1] 

机构地区：[1]四川省医学科学院．四川省人民医院保健科,610072

出　　处：《中国保健营养（临床医学学刊）》2009年第12期60-63,共4页China Health Care Nutrtion

摘　　要：目的评价信必可部保和舒利迭在治疗轻、中度支气管哮喘的临床疗效及安全性，并对二者的疗效加以比较。方法采用随机对照设计，㈤例支气管哮喘患者随机分为信必可都保组和舒利迭组，观察肺功能、临床疗效，进行治疗前后对比研究.结果两组药物都可改善患者的哮喘症状，但信必可都保组改善更快（p〈0.05）；肺功能方面，两组患者第1秒用力呼气量（FEV1）部有所提高，两组间无显著性差异，但信必可都保组对晨间呼气峰流速（PEF）提高显著快于舒利迭组（p〈0．05），两组不良事件的发生率无差别（p〉0.05）。结论信必可都保和舒利迭对支气管哮喘的症状和肺功能都有艮好的改善作用，但信必可都保起效时间更快。Objective To evaluate the effect and safety between Symbicort Turbuhaler and Seretide in the treatment of patients with bronchial asthma and compare the results. Methods Trabant comparative study was conducted to compare the clinical effect and safety of Symbicort Turbuhaler versus Seretide in the treatment of 80 cases on bronchial asthma, 40 patients received Symbicort Turbuhaler and the others received Seretide, the clinical symptoms, lung function and adverse-events were observed.保 Results improvement in asthma symptoms were observed in the two groups, improvement in Symbicort Turbuhaler groupn, is earlier than the control group （P〈0.05） .Both groups got improvement in forced expiratory volume in l s （FEVl）, and there was no difference in two groups. Symbicort Turbuhaler made rapid improvement in morning peak expiratory flow （PEF） compared to the control group （P〈0.05） .The two groups were similar in terms of advers-events （p〉0.05）. Conclusion Both Symbicort Turbuhaler and Seretide have good efficacy and safety, but Symbicort Turbuhaler had more rapid improvement than Seretide.

关 键 词：信必可都保 舒利迭 支气管哮喘 肺功能 疗效 

分 类 号：R562.2[医药卫生—呼吸系统]